Clinical trials: Esophagogastric Junction Disorder
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate postoperative adaptive adjuvant therapy in patients with gastric or gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy plus immunotherapy and radical…
- Trial name
- NCT07603349
- Testing
- Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants…
- Trial name
- FORTITUDE-101 (NCT05052801)
- Testing
- Bemarituzumab, mFOLFOX6
- Where
- 300 sites in United States, Argentina and 35 more
- Volunteers
- 547 people
- Sponsor
- Amgen
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
In Spain, the gastric carcinoma is the 5th most frequent malignant tumor in women and the 6th in men, and represents the 3rd cause of cancer-related deaths amongst women and the 4th amongst men.
- Trial name
- NCT01262482
- Testing
- Oxaliplatin, Sorafenib
- Where
- 10 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
- Trial name
- NCT00098527
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Pharmacokinetics of Zolbetuximab, Gastric Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer).
- Conditions
- Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin
- Trial name
- ILUSTRO (NCT03505320)
- Testing
- zolbetuximab, oxaliplatin, leucovorin
- Where
- 21 sites in United States, France and 4 more
- Volunteers
- 143 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Oesophageal Cancer Nos
- Trial name
- AROMA2 (NCT07260734)
- Testing
- Breath Test
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Gastric / Gastroesophageal Junction Adenocarcinoma
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with…
- Trial name
- G/GEJ (NCT07700979)
- Testing
- Cadonilimab, CAPOX regimen, Nivolumab
- Where
- 25 sites in United States, China and 2 more
- Volunteers
- 900 people
- Sponsor
- Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it.
- Trial name
- NCT04850729
- Testing
- non-intervention
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal…
- Trial name
- RILOMET-1 (NCT01697072)
- Testing
- Rilotumumab, Epirubicin, Cisplatin
- Where
- 189 sites in United States, Australia and 25 more
- Volunteers
- 609 people
- Sponsor
- Amgen
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Although the overall incidence of gastric cancer has steadily declined in many Western countries during the last few decades, it is still one of the most common tumors in China.
- Trial name
- NCT01364493
- Testing
- Trastuzumab+Capecitabine+Oxaliplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking University
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Esophagus Cancer, Esophagogastric Junction Cancer
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment…
- Trial name
- NCT02988921
- Testing
- MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer
- Trial name
- ARC-12 (NCT04772989)
- Testing
- AB308, Zimberelimab
- Where
- 22 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Arcus Biosciences, Inc.
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
This clinical trial test whether taking part in a diet support intervention will help with patients nutrition and quality of life after surgery for esophagus or stomach cancer.
- Trial name
- NCT05203627
- Testing
- Best Practice, Questionnaire Administration, Telemedicine Visit
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction
Preoperative chemoradiotherapy followed by surgery has been accepted as the standard of care for resectable adenocarcinoma of the esophagus and esophagogastric junction (EGJ).
- Trial name
- BoRgES (NCT04269083)
- Testing
- BIRC3
- Volunteers
- 128 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Gastric Cancer
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with…
- Trial name
- EXPAND (NCT00678535)
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- 130 sites in Argentina, Australia and 23 more
- Volunteers
- 904 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors, Gastric Cancer
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer
- Trial name
- NCT05275062
- Testing
- IM92 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.